37988-18-4

Basic information

• Product Name: LM 22A4
• Synonyms: N,N',N''-Tris(beta-hydroxyethyl)trimesamide;N1,N3,N5-Tris(2-hydroxyethyl)-1,3,5-benzenetricarboxamide;BD2-4
• CAS NO: 37988-18-4
• Molecular Formula: C₁₅H₂₁N₃O₆
• Molecular Weight: 339.34374
• EINECS: -0
• Product Categories: Agonist, Aromatics, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 37988-18-4.mol

Chemical Properties

• Appearance: white to beige/
• Storage Temp.: 2-8°C
• Solubility: H2O: soluble2mg/mL, clear (warmed)
• Stability: Stable for 1 year from date of purchase as supplied. Solutions in DMSO or distilled water may be stored at -20° for up to 1 month.
• CAS DataBase Reference: LM 22A4(CAS DataBase Reference)
• NIST Chemistry Reference: LM 22A4(37988-18-4)
• EPA Substance Registry System: LM 22A4(37988-18-4)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 37988-18-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
LM 22A4 is used as a neuroprotective agent for the treatment of neurodegenerative diseases. It promotes neuronal survival and prevents degeneration, making it a potential therapeutic candidate for conditions such as Alzheimer's, Parkinson's, and other related disorders.
Used in Traumatic Brain Injury Treatment:
LM 22A4 is used as a therapeutic agent to improve motor learning and cognitive function in individuals who have experienced traumatic brain injury. Its ability to activate TrkB signaling in the hippocampus and striatum of mice suggests its potential in enhancing recovery and rehabilitation processes.
Used in Rett Syndrome Treatment:
LM 22A4 is used as a therapeutic agent to improve respiratory function in mouse models of Rett syndrome. Its neurotrophic activity and TrkB agonist properties make it a promising candidate for the treatment of this neurodevelopmental disorder.
Used in Research and Development:
LM 22A4 is used as a research tool in the study of neurodegenerative diseases, traumatic brain injury, and Rett syndrome. Its ability to activate TrkB signaling and promote neuronal survival makes it a valuable compound for understanding the underlying mechanisms of these conditions and for the development of novel therapeutic strategies.

References

1) Massa et al. (2010), Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents; J. Clin. Invest., 120 1774 2) Schmid et al. (2012), A TrkB small molecule partial agonist rescues TrkB phosphorylation deficits and improves respiratory function in a mouse model of Rett syndrome; J. Neurosci., 32 1803

Upstream product

• 2672-58-4 1,3,5-tris-(methoxycarbonyl)benzene 
• 141-43-5 ethanolamine 
• 4422-95-1 1,3,5-benzene tris(carbonyl chloride) 

Relevant articles and documents

Acid-degradable solid-walled microcapsules for pH-responsive burst-release drug delivery

Acid-degradable microcapsules were prepared via an interfacial polymerization. Degradation of the thin wall of the capsules leads to all-or-nothing cargo release. The only byproducts of degradation are acetone, and a non-toxic triamide. Proof-of-concept experiments showed that cargo can be delivered to and released in cells. The Royal Society of Chemistry 2011.

Hierarchical Co-Assembly Enhanced Direct Ink Writing

Integrating intelligent molecular systems into 3D printing materials and transforming their molecular functions to the macroscale with controlled superstructures will unleash great potential for the development of smart materials. Compared to macromolecul